Designing CD4 immunoadhesins for AIDS therapy.

Abstract

A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.

• Authors: D J Capon, S M Chamow, J Mordenti, S A Marsters, T Gregory, H Mitsuya, R A Byrn, C Lucas, F M Wurm, J E Groopman
• Journal: Nature (Nature) Vol. 337 Issue 6207 Pg. 525-31 (Feb 09 1989) ISSN: 0028-0836 [Print] England
• PMID: 2536900 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Adjuvants, Immunologic
• Antigens, Surface
• Cell Adhesion Molecules
• HIV Envelope Protein gp120
• Immunoglobulin G
• Receptors, Complement
• Receptors, Fc
• Receptors, HIV
• Receptors, Virus
• Retroviridae Proteins

Topics

• Acquired Immunodeficiency Syndrome (immunology, metabolism, therapy)
• Adjuvants, Immunologic (chemical synthesis, metabolism, pharmacokinetics)
• Animals
• Antigens, Surface (administration & dosage, chemical synthesis, immunology)
• Binding Sites, Antibody
• Binding, Competitive
• Cell Adhesion Molecules
• Cell Line
• Drug Design
• HIV Envelope Protein gp120
• Half-Life
• Humans
• Immunoglobulin G (administration & dosage, metabolism)
• Mice
• Rabbits
• Receptors, Complement (analysis)
• Receptors, Fc (analysis)
• Receptors, HIV
• Receptors, Virus (administration & dosage, immunology)
• Retroviridae Proteins (metabolism)